Sunnybrook Research Institute (SRI) and Amylyx Pharmaceuticals have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
SK Biopharmaceuticals and Brazilian pharmaceutical firm Eurofarma have signed a license agreement to develop and commercialise cenobamate to treat epilepsy in Latin America.
Orion Biotechnology Canada, and Peptilogics have entered a research and development collaboration to leverage artificial intelligence (AI) for drug discovery against an undrugged G Protein-Coupled Receptors (GPCRs) target.
Inspirna has raised $50m in Series D financing round to advance the development of its clinical stage cancer drugs.
WuXi XDC has signed a Memorandum of Understanding (MOU) with Korean biotechnology firm AbTis to develop and manufacture a portfolio of antibody-drug conjugates (ADC) products.
Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies.
Turnstone Biologics has formed a broad strategic alliance with Moffitt Cancer Center for advancing the development of next-generation tumour-infiltrating lymphocyte (TIL) therapies for solid tumours.
UK-based Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Regeneron Pharmaceuticals has completed the purchase of Sanofi's stake in cancer drug Libtayo (cemiplimab).
Digital health start-up Mesh Bio has collaborated with drug discovery company MultiOmic Health to use artificial intelligence (AI) for developing precision medicines and diagnostics for chronic metabolic disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.